AI Article Synopsis

  • Posttraumatic epilepsy (PTE) affects about 10% of pediatric patients following traumatic brain injury (TBI), with certain factors like early seizures and severity of injury increasing risk.
  • A systematic review analyzed studies from major databases to clarify PTE incidence and associated risks, adhering to PRISMA guidelines.
  • Findings suggest that while PTE is a significant concern in children after TBI, more research is needed on risk factors and treatment approaches for better management.

Article Abstract

Posttraumatic epilepsy (PTE) is a well-known chronic complication following traumatic brain injury (TBI). Despite some evidence that age at the time of injury may influence the likelihood of PTE, the incidence of PTE in pediatric populations remains unclear. We therefore conducted a systematic review to determine the overall reported incidence of PTE, and explore potential risk factors associated with PTE after pediatric TBI. A comprehensive literature search of the PubMed, Embase, and Web of Science databases was conducted, including randomized controlled trials and cohort studies assessing the incidence of PTE in TBI pediatric patients. We excluded studies with a sample size of <10 patients and those in which a pediatric cohort was not clearly discernable. The review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We found that the overall incidence of PTE following pediatric TBI was 10% (95% confidence interval [CI] = 5.9%-15%). Subgroup analysis of a small number of studies demonstrated that the occurrence of early seizures (cumulative incidence ratio [CIR] = 7.28, 95% CI = 1.09-48.4, p = .040), severe TBI (CIR = 1.81, 95% CI = 1.23-2.67, p < .001), and intracranial hemorrhage (CIR = 1.60, 95% CI = 1.06-2.40, p = .024) increased the risk of PTE in this population. Other factors, including male sex and neurosurgical intervention, were nonsignificantly associated with a higher incidence of PTE. In conclusion, PTE is a significant chronic complication following childhood TBI, similar to in the adult population. Further standardized investigation into clinical risk factors and management guidelines is warranted. PROSPERO ID# CRD42021245802.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826023PMC
http://dx.doi.org/10.1111/epi.17398DOI Listing

Publication Analysis

Top Keywords

incidence pte
12
risk factors
8
posttraumatic epilepsy
8
traumatic brain
8
brain injury
8
systematic review
8
pte pediatric
8
pte
6
incidence
4
incidence risk
4

Similar Publications

Background: The significance of histological grading and peritumoral edema (PTE) in predicting intracranial meningioma recurrence among Saudis is often neglected. This study aimed to evaluate the impact of these factors over a 10-year follow-up period.

Methods: A retrospective cohort of 124 patients with intracranial meningioma was analyzed over the period from 2011 to 2021.

View Article and Find Full Text PDF

Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study.

JAMA Netw Open

January 2025

Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.

Importance: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels.

Objective: To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age.

Design, Setting, And Participants: This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]).

View Article and Find Full Text PDF

Polygenic risk scores for atrial fibrillation and heart failure and the risk of stroke and dementia.

Brain Commun

January 2025

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Mölndal 43139, Sweden.

Atrial fibrillation and heart failure have both been suggested to increase stroke and dementia risk. However, in observational studies, reversed causation and unmeasured confounding may occur. To mitigate these issues, this study aims to investigate if higher genetic risk for atrial fibrillation and heart failure increases dementia and stroke risk.

View Article and Find Full Text PDF

Epidemiology of DSM-5 PTSD and ICD-11 PTSD and complex PTSD in the Netherlands.

J Anxiety Disord

January 2025

Amsterdam UMC, Department of Psychiatry, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health, Amsterdam,  the Netherlands; ARQ National Psychotrauma Centre, Diemen, the Netherlands.

Introduction: Information regarding the prevalence of potentially traumatic events (PTEs), DSM-5 posttraumatic stress disorder (PTSD) and ICD-11 complex PTSD (CPTSD) in the Netherlands is currently lacking, as is data on treatment uptake and treatment barriers. We aimed to provide prevalence estimates for potentially traumatic events, PTSD and CPTSD in the Netherlands, describe treatment seeking behavior and explore associated risk factors.

Method: We included a sample of 1690 participants aged 16 years and older across the Netherlands via the Longitudinal Internet studies for the Social Sciences panel, a true probability sample of households drawn from the population register by Statistics Netherlands.

View Article and Find Full Text PDF

Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.

J Prev Alzheimers Dis

January 2025

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, BioClinicum, 171 64 Solna, Sweden; Theme Inflammation and Aging, Karolinska University Hospital, 141 86 Stockholm, Sweden.

The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and dementia specialists.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!